This 2026 multi-society clinical practice guideline covers the prevention, detection, evaluation, and management of cardiovascular-kidney-metabolic (CKM) syndrome — an integrated condition linking obesity, type 2 diabetes, chronic kidney disease, and cardiovascular disease. It replaces the 2013 AHA/ACC/TOS obesity guideline, drawing on a literature search spanning October 2024 to April 2025.
The guideline establishes CKM syndrome as a unified clinical framework and provides updated, evidence-based recommendations for cardiologists, endocrinologists, nephrologists, and primary care clinicians managing this interconnected condition.
The abstract does not detail specific recommendation grades, strength of evidence ratings, or individual clinical outcomes data. As a living document, recommendations are subject to future revision as new evidence emerges.
Clinicians should adopt the CKM syndrome framework to manage obesity, type 2 diabetes, CKD, and CVD as interrelated conditions rather than in silos. This guideline is a living document — check for updates as evidence evolves.
Explore related topics
